Monoclonal antibodies: Trends in therapeutic success and commercial focus

Michael S Kinch; Zachary Kraft; Tyler Schwartz

doi:10.1016/j.drudis.2022.103415

Monoclonal antibodies: Trends in therapeutic success and commercial focus

Drug Discov Today. 2023 Jan;28(1):103415. doi: 10.1016/j.drudis.2022.103415. Epub 2022 Oct 21.

Authors

Michael S Kinch¹, Zachary Kraft², Tyler Schwartz²

Affiliations

¹ Center for Research Innovation in Biotechnology, Long Island University, Brookville, NY 11548, USA. Electronic address: michael.kinch@liu.edu.
² Center for Research Innovation in Biotechnology, Long Island University, Brookville, NY 11548, USA.

PMID: 36280042
DOI: 10.1016/j.drudis.2022.103415

Abstract

Monoclonal antibody products have risen from obscurity in the 1990s to a position that increasingly dominates both revenue generation and patient impact. This success has occurred largely over the past two decades, and we have identified factors associated with the remarkable advances that have contributed to the discovery, development and approval of monoclonal antibodies. Although consolidation has increased in recent years, the net number of monoclonal antibody developers continues to grow, bucking the general trend in the biopharmaceutical industry.

Keywords: biologics; clinical trials; mechanism of action; monoclonal antibodies.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal* / therapeutic use
Humans

Substances

Antibodies, Monoclonal